Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mesenchymal stem cells
- Development stage
- Phase 2
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Local Implantation
01
Overview
Allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) are multipotent stromal cells isolated from donated human umbilical cord tissue and expanded in culture. These cells are investigated for their regenerative, anti-inflammatory, and immunomodulatory properties. Unlike autologous therapies, allogeneic UC-MSCs are sourced from unrelated donors, allowing for "off-the-shelf" availability. Their lower immunogenicity and strong immunosuppressive properties make them attractive for a range of indications. Clinical research has evaluated their safety and efficacy in diseases such as inflammatory bowel disease, chronic obstructive pulmonary disease, refractory epidermolysis bullosa, osteoarthritis, and others. Administration is typically intravenous or via local implantation, depending on the indication.
- Other names
- allogeneic UC-MSCsallogeneic umbilical cord mesenchymal stem cellsallogeneic human umbilical cord-derived mesenchymal stem cellshUCB-MSCs
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stem cells.